RSV shot uptake under the microscope: how many german babies get protected?
NCT ID NCT06824207
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tracks how many infants in Germany receive nirsevimab, a long-acting antibody that helps protect against severe RSV disease. Researchers will survey parents of babies born during three RSV seasons (2024–2027) to measure immunization rates. The goal is to see how well the new universal recommendation is being followed and to guide future vaccination strategies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nirsevimab
What this could lead to
If successful, this study could help public health officials understand how well RSV immunization is reaching infants, potentially improving future vaccination programs.
What could go wrong
This is an observational study that only measures immunization rates, not health outcomes. It cannot prove whether nirsevimab prevents severe RSV disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS IMMUNIZATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Germany, Germany, Germany